Michelle Srisuwananukorn, MD
Gastroenterology · Munster, INNPI 1609160464
Payments from drug & device makers
Across 642 payments — averaging $19.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Takeda Pharmaceuticals U.S.A., Inc.$909
- Johnson & Johnson$854
- Nestle Healthcare Nutrition Inc.$765
- Ironwood Pharmaceuticals, Inc$402
- plus $3K from 28 others
What the payments were for
- Consulting fees$1751%
- Speaking & faculty fees$3,35026%
- Food & beverage$9,18672%
- Education$160%
- Gifts$921%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 168 | $5,075 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 140 | $1,662 |
| Takeda Pharmaceuticals U.S.A., Inc. | 74 | $909 |
| Johnson & Johnson(3 entities) | 53 | $854 |
| Nestle Healthcare Nutrition Inc. | 64 | $765 |
| Ironwood Pharmaceuticals, Inc | 30 | $402 |
| Braintree Laboratories, Inc. | 10 | $355 |
| Olympus America Inc. | 2 | $285 |
| Janssen Scientific Affairs, LLC | 2 | $220 |
| Medtronic | 3 | $214 |
| Boston Scientific | 3 | $209 |
| Bristol Myers Squibb | 21 | $207 |
| Ambu Inc. | 2 | $197 |
| Romark Laboratories, LC | 5 | $162 |
| Gilead | 9 | $159 |
| Pfizer | 7 | $157 |
| Merck | 9 | $152 |
| Sanofi | 8 | $151 |
| Ardelyx, Inc. | 3 | $136 |
| Lilly USA, LLC | 4 | $87 |
| QOL Medical, LLC | 4 | $72 |
| Ferring Pharmaceuticals Inc. | 2 | $59 |
| Madrigal Pharmaceuticals | 3 | $50 |
| Phathom Pharmaceuticals, Inc. | 3 | $43 |
| Redhill Biopharma Inc. | 2 | $43 |
| Vivus LLC | 3 | $43 |
| Alfasigma USA, Inc. | 1 | $25 |
| Celltrion USA Inc. | 1 | $22 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| UCB, Inc. | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
| ERBE USA Inc | 1 | $17 |
| Evoke Pharma, Inc. | 1 | $17 |
| Novo Nordisk | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LINZESS$3,525
- Alinia$331
- SUTAB$220
- SUFLAVE$220
- STELARA$220
- EndoFlip$172
- Olympus Biliary Devices$162
- Monarch Platform$131
- VISIGLIDE$122
- CAPTIVATOR COLD$101
- XIFAXAN$100
How this compares
$12,820 in reported general payments places this provider in the 80th percentile of 323 gastroenterology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 40 | $1,191,421 |
| CreonLipase/Protease/Amylase | 21 | $73,585 |
| LinzessLinaclotide | 63 | $73,581 |
| ZenpepLipase/Protease/Amylase | 17 | $59,830 |
| XifaxanRifaximin | 12 | $27,367 |
| Mesalamine | 23 | $17,479 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 39 | $6,171 |
| Pantoprazole Sodium | 363 | $6,063 |
| Dexlansoprazole DrDexlansoprazole | 16 | $5,439 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 70 | $3,947 |
| Mesalamine ErMesalamine | 12 | $3,666 |
| Omeprazole | 179 | $2,182 |
| Lubiprostone | 16 | $1,897 |
| Sucralfate | 21 | $1,644 |
| Budesonide EcBudesonide | 12 | $1,583 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $854 | $1,191,42140 claims |
| AbbVieCreon, Linzess | $5,075 | $147,16684 claims |
| Aimmune Therapeutics, Inc.Zenpep | $19 | $59,83017 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $1,662 | $27,36712 claims |
| Braintree Laboratories, Inc.Sutab | $355 | $6,17139 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 323 gastroenterology providers in Indiana.
Other gastroenterology in Munster
- Anoop AppannagariMunster$120K
- Priti NuthakkiMunster$17K
- Gene ChangMunster$14K
- Navin KumarMunster$12K
- Monika FischerIndianapolis$2.8M
- Douglas RexIndianapolis$2.3M
- Pankaj PatelSouth Bend$2.3M
- David PoundIndianapolis$1.4M
- Naga ChalasaniIndianapolis$1.1M
- Sashidhar SagiWestfield$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.